Homozygous IL37 mutation associated with infantile inflammatory bowel disease
- Proc Natl Acad Sci U S A. 2021 Mar 9;118(10):e2009217118. doi: 10.1073/pnas.2009217118.
- 1. National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892.
- 2. Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge CB2 0AW, United Kingdom.
- 3. School of Medicine, Marmara University, 34722 Istanbul, Turkey.
- 4. Regeneron Genetics Center, Tarrytown, NY 10591.
- 5. National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892; [email protected].
Interleukin (IL)-37, an antiinflammatory IL-1 family cytokine, is a key suppressor of innate immunity. IL-37 signaling requires the heterodimeric IL-18R1 and IL-1R8 receptor, which is abundantly expressed in the gastrointestinal tract. Here we report a 4-mo-old male from a consanguineous family with a homozygous loss-of-function IL37 mutation. The patient presented with persistent diarrhea and was found to have infantile inflammatory bowel disease (I-IBD). Patient cells showed increased intracellular IL-37 expression and increased proinflammatory cytokine production. In cell lines, mutant IL-37 was not stably expressed or properly secreted and was thus unable to functionally suppress proinflammatory cytokine expression. Furthermore, induced pluripotent stem cell-derived macrophages from the patient revealed an activated macrophage phenotype, which is more prone to lipopolysaccharide and IL-1β stimulation, resulting in hyperinflammatory tumor necrosis factor production. Insights from this patient will not only shed light on monogenic contributions of I-IBD but may also reveal the significance of the IL-18 and IL-37 axis in colonic homeostasis.